Terms: = Breast cancer AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH
595 results:
1. [Clinical characteristics and prognostic factors of breast cancer patients with tumor deposits in the ipsilateral axillary region].
Xiao JJ; Huang ML; Yan CJ; Ling R; Wei HL
Zhonghua Zhong Liu Za Zhi; 2024 Feb; 46(2):146-154. PubMed ID: 38418189
[No Abstract] [Full Text] [Related]
2. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
[TBL] [Abstract] [Full Text] [Related]
3. Socio-cultural and financial issues against breast cancer screening behaviour among eligible Indian women: evidence for action.
Gupta S; Sinha Gupta S; De A; Banerjee R; Goel S
Breast Cancer Res Treat; 2024 May; 205(1):169-179. PubMed ID: 38347257
[TBL] [Abstract] [Full Text] [Related]
4. Health-related quality of life of premenopausal young breast cancer survivors undergoing endocrine therapy.
Lee K; Jun HS
Eur J Oncol Nurs; 2024 Feb; 68():102496. PubMed ID: 38194899
[TBL] [Abstract] [Full Text] [Related]
5. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
Wang Y; Dackus GMHE; Rosenberg EH; Cornelissen S; de Boo LW; Broeks A; Brugman W; Chan TWS; van Diest PJ; Hauptmann M; Ter Hoeve ND; Isaeva OI; de Jong VMT; Jóźwiak K; Kluin RJC; Kok M; Koop E; Nederlof PM; Opdam M; Schouten PC; Siesling S; van Steenis C; Voogd AC; Vreuls W; Salgado RF; Linn SC; Schmidt MK
BMC Med; 2024 Jan; 22(1):9. PubMed ID: 38191387
[TBL] [Abstract] [Full Text] [Related]
6. "All in one" nanoprobe Au-ttf-1 for target FL/CT bioimaging, machine learning technology and imaging-guided photothermal therapy against lung adenocarcinoma.
Yang Z; Zhang Y; Tang L; Yang X; Song L; Shen C; Zvyagin AV; Li Y; Yang B; Lin Q
J Nanobiotechnology; 2024 Jan; 22(1):22. PubMed ID: 38184620
[TBL] [Abstract] [Full Text] [Related]
7. The impact of metabolic syndrome in breast reconstruction decision-making and postoperative outcomes: A nationwide analysis.
Escobar-Domingo MJ; Bustos VP; Kim EJ; Campbell T; Fanning JE; Foppiani JA; Merle C; Lin SJ; Lee BT
J Plast Reconstr Aesthet Surg; 2024 Feb; 89():21-29. PubMed ID: 38128370
[TBL] [Abstract] [Full Text] [Related]
8. Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study.
Nakamoto S; Shien T; Itoh M; Yamamoto Y; Ohsumi S; Yoshitomi S; Hikino H; Miyoshi K; Notsu A; Taira N; Doihara H; Ikeda M
Clin Exp Med; 2023 Dec; 23(8):5129-5138. PubMed ID: 37904008
[TBL] [Abstract] [Full Text] [Related]
9. Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase.
Inui N; Toi Y; Yoneshima Y; Morise M; Hata A; Kubota K; Saeki T; Tamura T
Adv Ther; 2023 Nov; 40(11):4928-4944. PubMed ID: 37715851
[TBL] [Abstract] [Full Text] [Related]
10. Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer.
Wang Y; Ronckers CM; van Leeuwen FE; Moskowitz CS; Leisenring W; Armstrong GT; de Vathaire F; Hudson MM; Kuehni CE; Arnold MA; Demoor-Goldschmidt C; Green DM; Henderson TO; Howell RM; Ehrhardt MJ; Neglia JP; Oeffinger KC; van der Pal HJH; Robison LL; Schaapveld M; Turcotte LM; Waespe N; Kremer LCM; Teepen JC;
Nat Med; 2023 Sep; 29(9):2268-2277. PubMed ID: 37696934
[TBL] [Abstract] [Full Text] [Related]
11. Coping Strategies and Associated Symptom Burden Among Patients With Advanced cancer.
Dev R; Agosta M; Fellman B; Reddy A; Baldwin S; Arthur J; Haider A; Carmack C; Hui D; Bruera E
Oncologist; 2024 Feb; 29(2):166-175. PubMed ID: 37669020
[TBL] [Abstract] [Full Text] [Related]
12. Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study.
Wang M; Mao M; Yang Y; Cai Z; Li Y; Chen Y; Cai J; Ye Q
Future Oncol; 2023 Aug; 19(25):1729-1739. PubMed ID: 37650748
[No Abstract] [Full Text] [Related]
13. Description of characteristics, management of care and healthcare direct costs of patients with HR+/HER2- early breast cancer in Italy: a real-world study involving administrative and pathological anatomy databases.
Perrone V; Giacomini E; Sangiorgi D; Tamma A; Giovannitti M; Buzzoni C; Degli Esposti L
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(9):1077-1085. PubMed ID: 37638590
[TBL] [Abstract] [Full Text] [Related]
14. breast Magnetic Resonance Imaging for Preoperative Evaluation of breast cancer: A Systematic Review and Meta-Analysis.
Eisen A; Fletcher GG; Fienberg S; George R; Holloway C; Kulkarni S; Seely JM; Muradali D
Can Assoc Radiol J; 2024 Feb; 75(1):118-135. PubMed ID: 37593787
[No Abstract] [Full Text] [Related]
15. CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis.
Behrouzi R; Armstrong AC; Howell SJ
Breast Cancer Res Treat; 2023 Nov; 202(1):83-95. PubMed ID: 37584881
[TBL] [Abstract] [Full Text] [Related]
16. Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
Masuyama M; Masuda N; Kawaguchi H; Yamamoto Y; Saji S; Nakayama T; Aogi K; Anan K; Ohtani S; Sato N; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita T; Yotsumoto D; Toi M; Ohno S
Cancer Med; 2023 Sep; 12(17):17718-17730. PubMed ID: 37525895
[TBL] [Abstract] [Full Text] [Related]
17. Lung cancer with breast metastasis: a case report and review of the literature.
Cao X; Chen P; Agyekum EA; Zhang Q; Qian X; Wu T; Chambers KH; Yin L
J Int Med Res; 2023 Jul; 51(7):3000605231188287. PubMed ID: 37523488
[TBL] [Abstract] [Full Text] [Related]
18. Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic breast cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.
Munzone E; Regan MM; Cinieri S; Montagna E; Orlando L; Shi R; Campadelli E; Gianni L; Palleschi M; Petrelli F; Bengala C; Generali D; Collovà E; Puglisi F; Cretella E; Zamagni C; Chini C; Ruepp B; Loi S; Colleoni M;
JAMA Oncol; 2023 Sep; 9(9):1267-1272. PubMed ID: 37440239
[TBL] [Abstract] [Full Text] [Related]
19. Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer.
Bender L; Pflumio C; Trensz P; Pierard L; Kalish M; Fischbach C; Petit T
Cancer Treat Res Commun; 2023; 36():100738. PubMed ID: 37390791
[TBL] [Abstract] [Full Text] [Related]
20. Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation.
Takada S; Maeda H; Umehara K; Kuwahara S; Yamamoto M; Tomioka N; Takahashi M; Watanabe K; Hashishita H
Asian Pac J Cancer Prev; 2023 Jun; 24(6):1955-1962. PubMed ID: 37378924
[TBL] [Abstract] [Full Text] [Related]
[Next]
